Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.
ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
Signature of the participation consent to the study,
Affiliation to a social security scheme
metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment
Pregnant woman
Patient deprived of liberty by court or administrative decision
In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy
Refusal to participate in the study
Single group
blood samples collection
Biological/VaccineSerology and genetic analyses will be performed in patients blood samples
Percentage of successfull PDX
PDX will be realized from patient tumor by transplanting a small fragment in a nude mouse. Once the tumor is enough grown up, the tumor is extracted to repeat this step 3 times until we get the fourth PDX with a successful tumor growth.
Histological subtype
Comparaison of initial tumor histological subtype with PDX histological subtype
expression of estrogen receptors
Comparaison of initial tumor expression of estrogen receptors with PDX expression of estrogen receptors
expression of progesterone receptors
Comparaison of initial tumor expression of progesterone receptors with PDX expression of progesterone receptors
status of the amplification of the ERBB2 gene
Comparaison of initial tumor's ERBB2 gene amplification status with PDX's ERBB2 gene amplification status
Click on the lead sponsor to view all of their trials.
